212 related articles for article (PubMed ID: 24882718)
1. Alternative approaches to prevent androgen action in prostate cancer: are we there yet?
Elbanna M; Heemers HV
Discov Med; 2014 May; 17(95):267-74. PubMed ID: 24882718
[TBL] [Abstract][Full Text] [Related]
2. Androgen action in the prostate gland.
Yadav N; Heemers HV
Minerva Urol Nefrol; 2012 Mar; 64(1):35-49. PubMed ID: 22402316
[TBL] [Abstract][Full Text] [Related]
3. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
4. Differential androgen receptor signals in different cells explain why androgen-deprivation therapy of prostate cancer fails.
Niu Y; Chang TM; Yeh S; Ma WL; Wang YZ; Chang C
Oncogene; 2010 Jun; 29(25):3593-604. PubMed ID: 20440270
[TBL] [Abstract][Full Text] [Related]
5. Androgen receptor as a therapeutic target.
Gao W
Adv Drug Deliv Rev; 2010 Oct; 62(13):1277-84. PubMed ID: 20708648
[TBL] [Abstract][Full Text] [Related]
6. Targeting androgen receptor action for prostate cancer treatment: does the post-receptor level provide novel opportunities?
Heemers HV
Int J Biol Sci; 2014; 10(6):576-87. PubMed ID: 24948870
[TBL] [Abstract][Full Text] [Related]
7. A novel selective androgen receptor modulator (SARM) MK-4541 exerts anti-androgenic activity in the prostate cancer xenograft R-3327G and anabolic activity on skeletal muscle mass & function in castrated mice.
Chisamore MJ; Gentile MA; Dillon GM; Baran M; Gambone C; Riley S; Schmidt A; Flores O; Wilkinson H; Alves SE
J Steroid Biochem Mol Biol; 2016 Oct; 163():88-97. PubMed ID: 27106747
[TBL] [Abstract][Full Text] [Related]
8. Structures of androgen receptor bound with ligands: advancing understanding of biological functions and drug discovery.
Sakkiah S; Ng HW; Tong W; Hong H
Expert Opin Ther Targets; 2016 Oct; 20(10):1267-82. PubMed ID: 27195510
[TBL] [Abstract][Full Text] [Related]
9. Identification of a RhoA- and SRF-dependent mechanism of androgen action that is associated with prostate cancer progression.
Heemers HV
Curr Drug Targets; 2013 Apr; 14(4):481-9. PubMed ID: 23469924
[TBL] [Abstract][Full Text] [Related]
10. The importance of non-nuclear AR signaling in prostate cancer progression and therapeutic resistance.
Zarif JC; Miranti CK
Cell Signal; 2016 May; 28(5):348-356. PubMed ID: 26829214
[TBL] [Abstract][Full Text] [Related]
11. Plumbagin improves the efficacy of androgen deprivation therapy in prostate cancer: A pre-clinical study.
Abedinpour P; Baron VT; Chrastina A; Rondeau G; Pelayo J; Welsh J; Borgström P
Prostate; 2017 Dec; 77(16):1550-1562. PubMed ID: 28971491
[TBL] [Abstract][Full Text] [Related]
12. Androgen deprivation therapy for advanced prostate cancer: why does it fail and can its effects be prolonged?
Singer EA; Golijanin DJ; Messing EM
Can J Urol; 2008 Dec; 15(6):4381-7. PubMed ID: 19046491
[TBL] [Abstract][Full Text] [Related]
13. Manipulation of androgens and alterations in the androgen receptor axis in prostate cancer.
Nguyen MM; Wang Z
Minerva Urol Nefrol; 2008 Mar; 60(1):15-29. PubMed ID: 18427432
[TBL] [Abstract][Full Text] [Related]
14. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
Vis AN; Schröder FH
BJU Int; 2009 Aug; 104(4):438-48. PubMed ID: 19558559
[TBL] [Abstract][Full Text] [Related]
15. Androgen receptor structural and functional elements: role and regulation in prostate cancer.
Dehm SM; Tindall DJ
Mol Endocrinol; 2007 Dec; 21(12):2855-63. PubMed ID: 17636035
[TBL] [Abstract][Full Text] [Related]
16. Testosterone boosts for treatment of castration resistant prostate cancer: an experimental implementation of intermittent androgen deprivation.
Thelen P; Heinrich E; Bremmer F; Trojan L; Strauss A
Prostate; 2013 Nov; 73(15):1699-709. PubMed ID: 23868789
[TBL] [Abstract][Full Text] [Related]
17. Androgen action and metabolism in prostate cancer.
Green SM; Mostaghel EA; Nelson PS
Mol Cell Endocrinol; 2012 Sep; 360(1-2):3-13. PubMed ID: 22453214
[TBL] [Abstract][Full Text] [Related]
18. Cell-by-cell quantification of the androgen receptor in benign and malignant prostate leads to a better understanding of changes linked to cancer initiation and progression.
Derderian S; Benidir T; Scarlata E; Altaylouni T; Hamel L; Zouanat FZ; Brimo F; Aprikian A; Chevalier S
J Pathol Clin Res; 2023 Jul; 9(4):285-301. PubMed ID: 37073437
[TBL] [Abstract][Full Text] [Related]
19. Analyzing the Androgen Receptor Interactome in Prostate Cancer: Implications for Therapeutic Intervention.
Dahiya UR; Heemers HV
Cells; 2022 Mar; 11(6):. PubMed ID: 35326387
[TBL] [Abstract][Full Text] [Related]
20. Androgen receptor: role and novel therapeutic prospects in prostate cancer.
Taplin ME
Expert Rev Anticancer Ther; 2008 Sep; 8(9):1495-508. PubMed ID: 18759700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]